Truist analyst Richard Newitter raised the firm’s price target on iRhythm (IRTC) to $146 from $120 and keeps a Buy rating on the shares. The firm cites the company’s revenue and EBITDA beat thanks to Zio outperformance and guidance raise on a higher U.S. growth outlook, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm Technologies Reports Strong Q1 2025 Growth
- Apple downgraded, Reddit upgraded: Wall Street’s top analyst calls
- iRhythm price target raised to $150 from $133 at Baird
- iRhythm price target raised to $140 from $135 at BTIG
- Irhythm Technologies: Strong Performance and Growth Potential Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue